CV
CVALF.US Covalon Technologies Ltd
- Market cap
- USD 81.2M
- P/E
- 24.5x
- P/B
- 3.64x
- ROE
- 17.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Jun 2026.
Is CVALF.US undervalued?
Graham numberCVALF.US trades 99.0% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Covalon Technologies Ltd fundamental analysis
No fundamental analysis for Covalon Technologies Ltd yet.
Covalon Technologies Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Covalon Technologies Ltd
Covalon Technologies Ltd. engages in the research, development, manufacturing, and marketing of medical products in infection management, advanced wound care, and surgical procedure areas in the United States, the Middle East, Canada, Latin America, Asia, and internationally. The company's platform technologies comprises collagen matrix platform that is used to manufacture a family of products to treat chronic and infected wounds, including diabetic ulcers, pressure ulcers, …
Full company profileCovalon Technologies Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Covalon Technologies Ltd annual financial statements (CAD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 6.71M | 27.3M | 26.7M | 34.0M | 25.8M | 19.6M | 18.1M | 26.6M | 31.2M | 32.8M | 34.2M |
| Gross Profit | 4.15M | 21.0M | 19.7M | 21.8M | 12.5M | 9.70M | 7.49M | 14.4M | 18.9M | 17.5M | 21.5M |
| Operating Income | -2.97M | 1.81M | 1.62M | -8.25M | -6.09M | 838K | -9.14M | -4.53M | 2.15M | 1.76M | 4.93M |
| EBITDA | - | 2.08M | 1.97M | -7.62M | -4.89M | 1.54M | -8.11M | -3.56M | 3.14M | 2.72M | 5.92M |
| Net Income | -3.10M | 1.81M | 1.62M | -9.14M | -6.95M | 23.5M | -9.66M | -4.46M | 2.67M | 2.06M | 5.37M |
| EPS | - | 0.08 | 0.07 | -0.35 | -0.27 | 0.91 | -0.38 | -0.18 | 0.10 | 0.08 | 0.19 |
| Balance Sheet | |||||||||||
| Total Assets | 6.49M | 12.0M | 19.7M | 39.6M | 34.7M | 40.6M | 30.4M | 24.9M | 31.8M | 36.1M | 36.6M |
| Total Liabilities | 2.68M | 2.99M | 6.58M | 24.7M | 25.6M | 7.21M | 6.15M | 6.11M | 4.30M | 5.40M | 5.03M |
| Shareholders' Equity | 3.81M | 8.98M | 13.1M | 14.9M | 9.11M | 33.4M | 24.2M | 18.8M | 27.5M | 30.7M | 31.5M |
| Cash & Short-term Investments | 0.00 | 0.00 | 0.00 | 9.58M | 3.51M | 22.9M | 14.1M | 8.79M | 16.7M | 17.4M | 19.4M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -1.03M | 15.1K | -604K | -2.83M | -4.03M | 307K | -8.38M | -3.18M | 3.47M | 2.29M | 9.93M |
| Capital Expenditure | 252K | 300K | 726K | 1.26M | 206K | 176K | 600K | 1.32M | 417K | 847K | 1.67M |
| Free Cash Flow | - | -345K | -1.40M | -4.11M | -4.40M | 444K | -9.08M | -4.50M | 3.06M | 1.44M | 8.26M |
| Ratios | |||||||||||
| ROE | -81.3% | 20.2% | 12.3% | -61.2% | -76.3% | 70.3% | -39.9% | -23.7% | 9.7% | 6.7% | 17.0% |
| ROA | -47.7% | 15.1% | 8.2% | -23.1% | -20.0% | 57.9% | -31.8% | -17.9% | 8.4% | 5.7% | 14.7% |
| Net Profit Margin | -46.1% | 6.6% | 6.1% | -26.9% | -26.9% | 120.0% | -53.3% | -16.8% | 8.6% | 6.3% | 15.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Covalon Technologies Ltd dividends
Covalon Technologies Ltd has not paid dividends in the last 9 fiscal years.
Last stock split: 1:10 on Jul 16, 2013.
Who owns Covalon Technologies Ltd
- Insiders 47.16%
- Institutions 0.00%
- Public & others 52.84%
- Shares outstanding 27.6M
- Free float 16.5M
Covalon Technologies Ltd company profile
- Company name
- Covalon Technologies Ltd
- Ticker
- CVALF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- September
- Address
- 1660 Tech Avenue, Mississauga, ON, Canada, L4W 5S7
- Phone
- 905-568-8400
- Website
- covalon.com
About Covalon Technologies Ltd
Covalon Technologies Ltd. engages in the research, development, manufacturing, and marketing of medical products in infection management, advanced wound care, and surgical procedure areas in the United States, the Middle East, Canada, Latin America, Asia, and internationally. The company's platform technologies comprises collagen matrix platform that is used to manufacture a family of products to treat chronic and infected wounds, including diabetic ulcers, pressure ulcers, venous ulcers, donor and graft sites, traumatic wounds healing by secondary intention, dehisced surgical wounds, and first and second degree burns; and antimicrobial silicone adhesive platform, which is used for family of pre- and post-surgical, and vascular access products that are designed to kill bacteria or yeast that comes into contact with the antimicrobial silicone. It also offers a medical coating platform, a process that utilizes photo-polymerization to create active grafting sites where new polymer chains are initiated and propagated from the surface of an existing medical device. In addition, the company provides advanced wound care, antimicrobial dressings, collagen dressings, IV dressings, perioperative dressings, silicone dressings, vascular access line guards, and wound dressings; and surgical, peri-operative, and infection management products. It sells its products directly and through independent distributors under the ColActive, ColActive PLUS, CovaWound, CovaView, CovaClear IV, IV Clear, SurgiClear, MediClear, and VALGuard brands. The company serves health care providers, such as hospitals, wound care centers, burn centers, extended/alternate care facilities, acute care facilities, home health care agencies, and physicians' offices. Covalon Technologies Ltd. is headquartered in Mississauga, Canada.
Covalon Technologies Ltd management
9- Mr. Brent AshtonCEO & Director
- Dr. Valerio DiTizioCo-Founder, Chief Scientific Officer & VP · born 1968
- Ms. Katie MartinovichChief Financial Officer
- Ms. Kimberley CrooksCOO & Director
- Ms. Kerri KelleyVice President of Marketing
- Mr. Greg LeszczynskiVice President of Human Resources
- Gerry ArambulaPresident of Covalon Technologies AG Ltd.
- Mr. Hamed AbbasianVice President of Business Development
- Saleha AssadzadaExecutive Assistant to the CEO